Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash from Operations: 2016-2025

Historic Cash from Operations for Anaptysbio (ANAB) over the last 10 years, with Sep 2025 value amounting to -$27.4 million.

  • Anaptysbio's Cash from Operations fell 171.12% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.0 million, marking a year-over-year decrease of 40.73%. This contributed to the annual value of -$135.3 million for FY2024, which is 12.03% down from last year.
  • As of Q3 2025, Anaptysbio's Cash from Operations stood at -$27.4 million, which was up 32.02% from -$40.2 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Cash from Operations registered a high of $9.6 million during Q2 2021, and its lowest value of -$66.7 million during Q4 2024.
  • Moreover, its 3-year median value for Cash from Operations was -$27.4 million (2025), whereas its average is -$30.4 million.
  • In the last 5 years, Anaptysbio's Cash from Operations surged by 148.91% in 2021 and then plummeted by 351.77% in 2022.
  • Anaptysbio's Cash from Operations (Quarterly) stood at -$25.3 million in 2021, then surged by 57.77% to -$10.7 million in 2022, then plummeted by 221.47% to -$34.3 million in 2023, then plummeted by 94.10% to -$66.7 million in 2024, then tumbled by 171.12% to -$27.4 million in 2025.
  • Its Cash from Operations stands at -$27.4 million for Q3 2025, versus -$40.2 million for Q2 2025 and -$10.7 million for Q1 2025.